Objective: To determine how out-of-pocket costs for adjuvant endocrine therapy (AET) medication affects adherence among newly diagnosed breast cancer survivors with private health insurance who initiate therapy.
strogen receptor-positive (ER +) breast cancer is present in two-thirds of breast cancer cases in the United States. 1, 2 In addition to a combination of surgery, chemotherapy and/or radiation, the standard of care for ER + breast cancer for postmenopausal women is endocrine therapy with third generation aromatase inhibitors (AIs) such as exemestane, anastrozole, or letrozole for 5 years. [3] [4] [5] [6] Similarly, the National Comprehensive Cancer Network at the time of the study period recommended that premenopausal women receive treatment with tamoxifen for up to 5 years or until menopause at which time women may switch to the AIs. 6 Treatment with adjuvant endocrine therapy (AET: AIs and/ or tamoxifen) has been demonstrated to reduce the risk of subsequent breast cancer and the rate of mortality versus nonusers in both clinical trials and in diverse population-based cohorts of women in clinical practice. 4, [7] [8] [9] [10] Compared with nonusers, the reduction in subsequent breast cancer risk ranges from 40% to 66% across the AET groups depending on the degree of adherence. 9 Treatment with tamoxifen for 5 years has been shown to reduce the rate of recurrence by 39% throughout the first decade, and reduces breast cancer mortality by about one-third throughout the first 15 years. 10 However, women with a prescription benefit plan who discontinued AET early, were nonadherent, had a significantly higher mortality rate compared with those who finished the full course of therapy. 11 Thus, this suggests that improvements in adherence rates to AET can reduce the morbidity and mortality of women with ER + breast cancer.
Despite the improvement in disease prognosis among patients treated with AET, approximately 21% to 50% of patients are nonadherent within 4 to 5 years. 12 In a retrospective longitudinal study, only 72% to 81% of patients were adherent (Medication Possession RatioZ80%) to anastrozole after 1 year with the mean percentage of adherent patients decreasing over a 3-year period. 13 Although studies have examined the association between copayments and adherence to AET, they do not include out-ofpocket costs such as the coinsurance or deductibles paid by the patient at the time of a prescription fill for AET, do not control for other out-of-pocket costs, and/or they examine women anytime during AET treatment rather than during the first year following breast cancer diagnosis and treatment. [14] [15] [16] [17] Therefore, we sought to measure 1-year adherence to AET among women diagnosed and surgically treated with breast cancer who initiate AET within the first year in a large commercially insured population and to determine, a priori, the association between combined out-ofpocket costs for AET medication and adherence.
MATERIALS AND METHODS

Data Source
a nation-wide, employer-based, commercially insured population in the United States. We used the Truven Health Analytics MarketScan Commercial Claims and Encounters Databases from January 1, 2007 to December 31, 2011. The MarketScan databases capture person-specific clinical utilization, expenditures, and enrollment across inpatient, outpatient, and prescription drug services. All data were deidentified in accordance with the Health Insurance Portability and Accountability Act requirements. Study procedures were conducted in accordance with the ethical standards of the institutional review board at the University of Washington.
Sample Selection
We identified women under the age of 64 with at least 1 prescription claim for an AI, or tamoxifen between January 1, 2008 and December 31, 2010 (Fig. 1) . Initiation of AET was defined as no AET prescription claims for at least 6 months before the first claim (index claim). Next, women were included in the cohort if they were diagnosed and surgically treated for breast cancer within 12 months before the index claim. Although AET treatment is recommended for up to 5 years, we were interested adherence after first initiation as a critical period for intervention. Breast cancer diagnosis was defined as a diagnostic International Classification of Diseases, Ninth Revisions, Clinical Modification code (ICD-9-CM) for ductal in situ carcinoma (ICD-9-CM: 233.0), primary invasive breast cancer (ICD-9-CM: 174.0 to 174.9) or primary invasive breast cancer with axillary lymph node involvement (ICD-9-CM: 196.0 to 196. 3, 196.5 to 196.6, or 196.8 to 196.9) in inpatient records. Surgical treatment was defined as an ICD-9-CM code or Current Procedural Terminology code (fourth edition) for bilateral mastectomy, mastectomy, or breast conserving surgery/lumpectomy. [18] [19] [20] We restricted our sample to women continuously enrolled in a health plan that included prescription drug coverage for at least 6 months before and 12 months after the index claim. We excluded women with a diagnosis of multiple primary cancers, metastatic breast cancer to distant organs, or breast cancer recurrence any time before initiation and during the study period.
Outcome
The primary outcome was medication adherence to AET calculated using the proportion of days covered (PDC). 21 We assumed women did not take more than 1 AET medication at a time. 22 PDC was calculated based on the fill dates and the number of days' supply for each prescription. The numerator was the total number of days covered by the prescription fill during the 12-month study period. We created coverage periods to reflect the dates that were encompassed by each prescription fill. We shifted the start date of each period so that women did not have overlapping days of coverage. We assumed that women did not take the refilled medication before exhausting the previous prescription. 23 The denominator was 365, the number of days between the index claim and the end of the follow-up study period (12 mo after the index claim). The ratio was multiplied by 100 to obtain the percentage of the PDC. We categorized patients as being adherent if the PDC was 80% or greater. 24 
Time to Discontinuation
We examined the time to AET discontinuation among patients considered nonadherent (PDC < 80%). We assumed that a woman discontinued AET if she went at least 4 consecutive months ( > 120 d) without medication. 13 A woman was considered to discontinue treatment the month in which she filled her last prescription; therefore we could only measure up to 8 months.
Out-of-Pocket Costs for AET
Mean out-of-pocket costs for a 30-day supply of AET medication were defined as the sum of the copayments, deductibles, and coinsurance paid by the subject at the time that the prescription was filled. Out-of-pocket cost amounts for 60-or 90-day prescriptions were adjusted to 30-day amounts. Out-of-pocket costs for AET were categorized into quintiles of <$4.99, $5.00 to $9.99, $10.00 to $14.99, $15.00 to 19.99, and >$20.00 based on common copayment amounts in multiples of $5 and so that each category represented an equivalent dollar amount and an approximately equal distribution of patients. As a sensitivity analysis for the category cut-points we included a continuous measure of AET out-of-pocket costs to determine if out-of-pocket costs were associated with adherence.
Other Out-of-Pocket Costs
Other out-of-pocket costs paid by the patient at the time services were rendered were calculated for inpatient and outpatient services, and pharmacy medications (excluding AET medication). Other out-of-pocket costs were calculated for each refill period and adjusted to reflect an average 30-day outof-pocket costs from the index date until the patient no longer had AET medication on-hand, up to 365 days. Other out-ofpocket costs for 30 days were categorized into quintiles of <$49.99, $50 to $99.99, $100 to $149.99, $150 to $199.99, and >$200 so that each category represented an equivalent dollar amount with an approximately even distribution of patients.
Comorbidities
We used the Elixhauser index to control for comorbidities using inpatient and outpatient diagnoses (IDC-9-CM codes) during the time period before the index date. 25 Subjects were assigned a value based on the number of comorbidities.
Additional Subject Characteristics
Subject characteristics were limited to those variables that were available in the MarketScan Database. Age in years was evaluated categorically (below 40, 40 to 49, 50 to 59, and 60 to 64 y of age) and a variable to indicate whether subjects used mail or retail pharmacy was calculated based at the index date. We created breast cancer treatment variables for surgery (bilateral mastectomy, mastectomy, or lumpectomy), and the receipt of chemotherapy and/or radiation using ICD-9-CM and Current Procedural Terminology codes from inpatient and outpatient claims up to 12 months before their first AET prescription fill. [18] [19] [20] We assessed whether women had an oophorectomy before initiating AET. We included a variable for the duration of time from surgical treatment to the index date (0 to 3, 4 to 6, 7 to 9, and 10 to 12 mo). Pill burden was calculated as the count of unique drug classes filled 90 days before the index date. We included a variable for geographic region (Northeast, North Central, South, and West), and health plan type (health maintenance organization, preferred provider organization, other). We determined if women switched AET medication if they filled a prescription for any other AI or tamoxifen different than the index drug and were categorized as not switched, switched once, or switched 2 or more times.
Statistical Analysis
Unadjusted differences in the percentage of nonadherent (PDC < 80%) and adherent (PDCZ80%) women were evaluated using the Pearson w 2 test for categorical variables. We used a multivariable logistic regression model with robust SE estimates to calculate the odds of being adherent to AET versus being nonadherent in a 1-year period. All previously described variables were included in the model and were considered to be clinically significant and potential confounders based on prior studies. [14] [15] [16] [17] 26 We used the direct substitution method to determine the adjusted risk ratio (ARR) and adjusted risk difference (ARD) as adherence was not considered to be a rare event thus avoiding inappropriately reporting odds ratios, which cannot be properly interpreted as the risk of an event in this setting. 27 The ARR is the ratio of the mean predicted probabilities and is a measure for the probability of adherence for each category of copayment after controlling for potential confounders. The ARD is the difference of the mean predicted probabilities and represents differences in the absolute risk of adherence. All analyses were conducted using Stata 13.1 SE (StatCorp, College Station, TX).
RESULTS
During the 3-year study period, 6863 women were identified in the MarketScan databases who were 64 years and younger and initiated AET following a diagnosis and surgical treatment of early breast cancer. Among this cohort, 26.1% of patients were nonadherent because they had fewer than 80% of AET medication days covered (PDC < 80%) during the first year of therapy. Table 1 lists characteristics of the study cohort by the proportion of subjects who were adherent to AET medication (PDCZ80%). In the cohort, 59% of the patients were between 50 and 64 years of age. The majority had early breast cancer without lymph node involvement (68%), were enrolled in a preferred provider organization health plan (60%), filled prescriptions using a retail pharmacy (84%), received chemotherapy treatment (57%), did not have a preexisting diagnosis of a major condition (62%), and did not switch AET during the 12-month follow-up period (84%). Half of the patients initially filled a prescription for tamoxifen (51%). The mean out-of-pocket costs for a 30 days' supply of AET medication was $17.10 (SD = 22.4) while the mean 30-day out-of-pocket costs for other prescriptions and inpatient and outpatient services was $176.50 (SD = 172.20).
In the unadjusted analysis, adherence to AET was associated with age, treatment with chemotherapy, geographical region, AET drug type, the number of times a patient switched AET medication, the number of prescription drugs filled 90 days before index date, and the pharmacy type that the patient used. A greater proportion of patients were less likely to be adherent to AET with increasing out-of-pocket costs for AET medication (P < 0.05). *Comorbidities presented were the most prevalent of the 30 Elixhauser conditions among members in the cohort. The Elixhauser comorbidities exclude metastatic cancer and solid tumors without metastasis as these were included as part of the exclusion criteria for cohort entry.
wP-values correspond to the Pearson w 2 for unadjusted analysis to test for differences between adherent and nonadherent proportions for each categorical variable.
zOther out-of-pocket costs include services for outpatient, inpatient, and medications (other than AET) during the follow-up period for which patients had AET medication on-hand.
AET indicates adjuvant endocrine therapy; DCIS, ductal carcinoma in situ; HMO, health maintenance organization; PDC, proportion of days covered; PPO, preferred provider organization. *Other out-of-pocket costs include services for outpatient, inpatient, and medications (other than AET) during the follow-up period for which patients had AET medication on-hand.
AET indicates adjuvant endocrine therapy; CI, confidence interval; DCIS, ductal carcinoma in situ; HMO, health maintenance organization; PPO, preferred provider organization.
interval [CI] , 0.88-0.98; ARR, 0.92; 95% CI, 0.85-0.98, and ARR, 0.94; 95% CI, 0.89-0.99, respectively). We observed the association for each category of out-of-pocket costs for AET medication except for patients with a $5.00 to $9.99 out-ofpocket cost for a 30 days' supply of AET medication. However, a sensitivity analysis was performed classifying out-ofpocket costs for AET as a continuous variable and the results were unchanged.
Copayments, deductibles, and coinsurance accounted for 46.3%, 18.6%, and 35.2%% of 30-day out-of-pocket costs for other prescription medication, and inpatient and outpatient services (data not shown). Other out-of-pocket costs were not associated with adherence to AET medication.
Other Patient Characteristics
Women age 60 to 64 were more likely to be adherent to AET compared with women below 39 years (ARR, 1.17; 95% CI, 1.11-1.22). Women in the geographical south (ARR, 0.89; 95% CI, 0.85-0.93) of the United States and the West (ARR, 0.94; 95% CI, 0.89-0.99) were significantly less likely to be adherent to AET compared with women in the Northeast. Women who used a mail pharmacy compared with a retail pharmacy for their first AET prescription fill were more likely to be adherent to AET (ARR, 1.15; 95% CI, 1.11-1.19). Patients were less likely to be adherent to AET for every increase in preexisting condition that a woman had (ARR, 0.98; 95% CI, 0.96-0.99) and for every time she switched AET medication (2 or more times vs. no switching ARR, 0.83; 95% CI, 0.73-0.95). Women with 10 to 12 months between surgical treatment and index claim were less likely to be adherent to AET compare with women with 0 to 3 months (ARR, 0.91; 95% CI, 0.84-0.98).
Time to Discontinuation
We examined the time to discontinuation of AET medication among women who were considered nonadherent (PDC < 80) (n = 1790). The mean PDC among nonadherent patients (PDC < 80) was 50%. Figure 2 depicts the percentage of patients, by month, who went >120 consecutive days without medication, considered to have discontinued AET. Among nonadherent patients, 19.1% discontinued after the first month of AET prescription fill. After 8 months, 46.7% of nonadherent patients discontinued therapy. Of the nonadherent women (PDC < 80%), 53.3% were not considered to have discontinued therapy but had intermittent prescription refills throughout the 12-month study period, although not enough to have Z80% of medication on-hand. Patients who discontinued therapy during the study period had a mean 30-day out-of-pocket costs for AET of $19.47, compared with $18.04 for women who were nonadherent but who had not discontinued therapy.
DISCUSSION
In this study, we found that 73.9% of women who initiated AET after a diagnosis of early breast cancer had filled prescriptions to have pills for at least 292 days (80%) over the first year. We observed that women with higher out-of-pocket costs for AET medication fills was significantly associated with a 6% to 8% lower likelihood of adherence to AET among a privately insured cohort of women with a prescription drug plan. The fact that low adherence is influenced by out-ofpocket costs for AET medication is important because low adherence to AET is associated with 10% to 49% higher breast cancer-specific mortality compared with women who are adherent. 11, 28 The finding on the association between higher out-ofpocket costs for AET and lower risk of adherence is similar to other retrospective cohort studies that have found, on average, copayments decrease the odds of adherence to AI's or tamoxifen. 13, 14, 16, 17 These studies, however, examined the effect of copayments and not total out-of-pocket costs. In our study, we found that 5% to 6% of the total out-of-pocket costs were from coinsurance and deductibles at the time of AET prescription fill. We found that patients with a categorical outof-pocket costs for AET medication Z$10 was associated with a lower odds of adherence compared with patients with <$4.99 out-of-pocket costs. In an exploratory analysis (results not shown) we observed that patients with <$10 out-of-pocket costs for AET medication was associated with filling a prescription for tamoxifen versus an AI and with filling a prescription using mail order pharmacies versus retail pharmacies. Tamoxifen drug costs tended to be cheaper than the AIs because a generic form of tamoxifen became available in 2002, before the study period. Studies suggest that the side-effects from tamoxifen may be more manageable compared with the side-effects from the AIs. 29, 30 Filling a prescription using mail order pharmacies may be more convenient and patients can often order in larger supplies (eg, 90 d) which is more economical. 31 However, despite these differences between the two groups of out-of-pocket costs, in a sensitivity analysis, a continuous variable for a $1 increase for a 30-day supply of AET medication was statistically associated with a decrease in the odds of adherence after adjusting for all other covariates.
In our study we did not find that out-of-pocket costs for other prescription pharmacy, and inpatient or outpatient services was associated with adherence. Sedjo and Devine 17 found that other out-of-pocket costs were associated with adherence to AET, however, out-of-pocket costs were included as the sum for the entire 12-month follow-up period even if women had discontinued filling prescriptions for AET, likely overinflating the association with adherence to AET medication. In our study we calculated other out-of-pocket costs as a 30-day average limited to the time that women had filled prescriptions for AET medication. This is important since over 1-quarter of the cohort were nonadherent.
Our findings on adherence rates are consistent with reports using similar claims-based methodology among insured women which found 12-month adherence to AET were ranged between 72% and 81% (Medication Possession RatioZ80%). 13, [15] [16] [17] We found that discontinuation among nonadherers (PDC < 80%) was greatest after the first month of initiation (19%) and then decreased to 4% to 7% per month, thereafter. This trend is similar to a study by Partridge et al 13 who found that the greatest percent of women who went >120 days without medication was after the first month, although continued to increase thereafter. In addition, we found that among nonadherers (PDC < 80%), over half of the patients (53.3%) had intermittently filled prescriptions throughout the 12-month follow-up but did not go >120 days without medication on-hand. Thus, in addition to pharmacists and oncologists encouraging women to regularly fill prescriptions, structural factors such as automated reminder calls particularly after the first month of AET initiation may increase subsequent refills.
Similar to other research studies, we found that, on average, older women, women who used mail order versus retail pharmacies, and women with fewer comorbidities was associated with a higher probability of adherence. 13, [15] [16] [17] Studies have also found that patients who experience side effects from AET are more likely to be nonadherent. 7, 8, 12, 32 In our study, there was a 15% decreased probability of adherence among women who switched AET medication once compared with those that did not switch (P < 0.001). In a chart review study, approximately 84% of breast cancer survivors who took anastrozole switched to another AI due to side effects. 33 Thus, medication switching may partially be correlated with medication side effects. We attempted to control for side effects from initial breast cancer treatment by including the time from surgery to initiation and found that the more time that elapsed, the more the probability of adherence decreased. This is an important finding because women who allow more time to elapse may have greater side-effects from initial treatment and leads them to delay initiating AET medication.
Our study had limitations. The measure of adherence using pharmacy claims is how much medication a woman has procured over a 12-month period, but may not reflect actual medication consumption and does not reflect issues such as lost medications. Clinical and prognostic factors such as date of diagnosis, stage of disease, and ER + status are not readily available from claims and billing data, therefore we had to develop procedural and diagnostic algorithms for these measures which may have misclassified patients. We do not know from claims if each woman in our sample had an appropriate indication for AET treatment. We assumed that if a woman filled a prescription for AET following treatment for a newly diagnosed nonmetastatic breast cancer, she met National Comprehensive Cancer Network treatment recommendations for AET and is likely to have ER + breast cancer. It is possible that the index date we identified may not have been their first AET fill, although we restricted our sample to women with no evidence of recurrent breast cancer and no evidence of prior AET use. Several potential predictors such as socioeconomic status factors and race/ethnicity were not available. Out-ofpocket costs for AET may be a surrogate for socioeconomic status factors, however, we did not find a significant difference between other out-of-pocket costs and adherence to AET as we did with out-of-pocket costs specific to AET medication therefore limiting the plausibility of this assumption. Unmeasured factor(s) such as side effects from initial treatment and AET medication may also be a contributing factor to the findings, however our inclusion of a variable to measure time from surgery to first prescription refill and medication switching may limit the impact of treatment side effects on adherence. Finally, all of the women in the study were commercially insured in a plan that offered prescription coverage and are likely healthier and younger than the general population of breast cancer patients.
Our findings have important implications. High out-ofpocket cost for AET medication are significantly associated with nonadherence and may put patients at an increased risk of cancer recurrence and increased morbidity if they cannot access medication. 4, 5, 9, 11 Further research should focus on interventions to lower out-of-pocket costs for AET medication by exploring the role that pharmacists can play by identifying patients that belong to plans that have high cost sharing and make recommendations to select generic versus brand name drugs that are in alternate drug plan tiers. 14 Even among commercially insured patients with a prescription drug plan in the United States, adherence to AET is suboptimal. Efforts to lower the out-of-pocket costs for AET medication could significantly improve adherence.
Percent of non-adherent women (n=1,790) Month of AET Prescription fill
Newly discontinued Discontinued (>120 days without AET medication) FIGURE 2. Proportion of nonadherent patients who went >120 consecutive days without medication on-hand, considered to have discontinued adjuvant endocrine therapy, (n = 1790). By definition, patients were considered to have discontinued AET medication if they had >120 days without medication on-hand and therefore patients could only be considered to have discontinued therapy up to 8 months after initial prescription fill. Patients were considered to have discontinued AET medication the month that they last filled medication. AET indicates adjuvant endocrine therapy.
